Clear cell Renal Cell Carcinoma (ccRCC) is characterized by
VHL inactivation1,2. Because no
other gene is mutated as frequently, and VHL mutations are
truncal3,
VHL inactivation is regarded as the governing
event4.
VHL loss activates HIF-2, and constitutive HIF-2 restores
tumorigenesis in VHL-reconstituted ccRCC cells5. HIF-2 is implicated in
angiogenesis and multiple other processes6–9, but
angiogenesis is the main target of drugs like sunitinib10. HIF-2, a transcription
factor, has been regarded as undruggable11. A structure-based design approach identified a
selective HIF-2 antagonist (PT2399) that we evaluate using a tumorgraft (TG)/PDX
platform12,13. PT2399 dissociated HIF-2 (an
obligatory heterodimer [HIF-2α/HIF-1β])14 in human ccRCC suppressing
tumorigenesis in 56% (10/18) lines. PT2399 had greater activity than
sunitinib, was active in sunitinib-progressing tumors, and was better tolerated.
Unexpectedly, some VHL-mutant ccRCCs were resistant. Resistance
occurred despite HIF-2 dissociation in tumors and evidence of Hif-2 inhibition
in the mouse as determined by suppression of circulating erythropoietin, a HIF-2
target15 and possible
pharmacodynamic marker. We identified a HIF-2-dependent gene signature in
sensitive tumors. Illustrating drug specificity, gene expression was largely
unaffected by PT2399 in resistant tumors. Sensitive tumors exhibited a
distinguishing gene expression signature, and generally higher HIF-2α
levels. Prolonged PT2399 treatment led to resistance. We identified a binding
site and second site suppressor mutation in HIF-2α and HIF-1β
respectively. Both mutations preserved HIF-2 dimers despite treatment with
PT2399. Finally, an extensively pretreated patient with a sensitive TG had
disease control for >11 months with the close analogue PT2385. We
validate HIF-2 as a target in ccRCC, show that some ccRCC are, unexpectedly,
HIF-2 independent, and set the stage for biomarker-driven clinical trials.
Purpose: The heterodimeric transcription factor HIF-2 is arguably the most important driver of clear cell renal cell carcinoma (ccRCC). Although considered undruggable, structural analyses at the University of Texas Southwestern Medical Center (UTSW, Dallas, TX) identified a vulnerability in the a subunit, which heterodimerizes with HIF1b, ultimately leading to the development of PT2385, a first-in-class inhibitor. PT2385 was safe and active in a first-in-human phase I clinical trial of patients with extensively pretreated ccRCC at UTSW and elsewhere. There were no dose-limiting toxicities, and disease control !4 months was achieved in 42% of patients.Patients and Methods: We conducted a prospective companion substudy involving a subset of patients enrolled in the phase I clinical trial at UTSW (n ¼ 10), who were treated at the phase II dose or above, involving multiparametric MRI, blood draws, and serial biopsies for biochemical, whole exome, and RNAsequencing studies.Results: PT2385 inhibited HIF-2 in nontumor tissues, as determined by a reduction in erythropoietin levels (a pharmacodynamic marker), in all but one patient, who had the lowest drug concentrations. PT2385 dissociated HIF-2 complexes in ccRCC metastases, and inhibited HIF-2 target gene expression. In contrast, HIF-1 complexes were unaffected. Prolonged PT2385 treatment resulted in the acquisition of resistance, and we identified a gatekeeper mutation (G323E) in HIF2a, which interferes with drug binding and precluded HIF-2 complex dissociation. In addition, we identified an acquired TP53 mutation elsewhere, suggesting a possible alternate mechanism of resistance.Conclusions: These findings demonstrate a core dependency on HIF-2 in metastatic ccRCC and establish PT2385 as a highly specific HIF-2 inhibitor in humans. New approaches will be required to target mutant HIF-2 beyond PT2385 or the closely related PT2977 (MK-6482).
The expanding use of the 2012 WHO criteria has been accompanied by an increased diagnostic frequency of benign phyllodes tumors and a decrease in fibroadenomas. As fibroepithelial diagnoses become more distinct, evidence-based management recommendations for less virulent phyllodes diagnoses should be developed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.